{"id":24891,"date":"2024-12-05T18:15:58","date_gmt":"2024-12-05T21:15:58","guid":{"rendered":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/"},"modified":"2024-12-05T18:15:58","modified_gmt":"2024-12-05T21:15:58","slug":"consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro","status":"publish","type":"post","link":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/","title":{"rendered":"Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro"},"content":{"rendered":"<p>O c\u00e2ncer de pulm\u00e3o \u00e9 o <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33818764\/\" data-mce-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33818764\/\">segundo tipo de c\u00e2ncer mais diagnosticado no mundo<\/a> e foi a principal causa de mortes por c\u00e2ncer em 2020. No <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/cancer\/tipos\/pulmao\" data-mce-href=\"https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/cancer\/tipos\/pulmao\">Brasil<\/a>, \u00e9 o terceiro mais comum em homens e o quarto em mulheres, totalizando <a data-mce-href=\"https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/cancer\/numeros\/estimativa\/estado-capital\/brasil\" href=\"https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/cancer\/numeros\/estimativa\/estado-capital\/brasil\">32.560 novos casos em 2023<\/a>, com uma taxa de sobrevida de 18% em cinco anos.<\/p>\n<p>J\u00e1 o subtipo de c\u00e2ncer de pulm\u00e3o n\u00e3o pequenas c\u00e9lulas (CPNPC) <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html\" data-mce-href=\"https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html\">corresponde a 80% &#8211; 85% dos casos<\/a>, sendo que cerca de <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25806345\/\" data-mce-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25806345\/\">5% desses pacientes<\/a> <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33314759\/\" data-mce-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33314759\/\">apresentam a transloca\u00e7\u00e3o ALK+<\/a>, uma muta\u00e7\u00e3o ultrarrara que acomete principalmente n\u00e3o fumantes. Pela aus\u00eancia de sintomas no in\u00edcio da doen\u00e7a, quem convive com o CPNPC geralmente <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)30925-9\/fulltext\" data-mce-href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)30925-9\/fulltext\">recebe o diagn\u00f3stico<\/a> <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/www.interfarma.org.br\/library\/cancer-in-brazil-the-patient-s-journey-in-the-healthcare-system-and-its-social-and-financial-impacts\/\" data-mce-href=\"https:\/\/www.interfarma.org.br\/library\/cancer-in-brazil-the-patient-s-journey-in-the-healthcare-system-and-its-social-and-financial-impacts\/\">em est\u00e1gio avan\u00e7ado<\/a> e, no caso dos pacientes com ALK+, cerca de <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26438117\/\" data-mce-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26438117\/\">30% j\u00e1 apresentam met\u00e1stases cerebrais<\/a>. Um verdadeiro desafio, pois a met\u00e1stase cerebral \u00e9 uma necessidade m\u00e9dica ainda n\u00e3o atendida totalmente pelos tratamentos dispon\u00edveis no SUS, que <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30416687\/\" data-mce-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30416687\/\">compromete e diminui<\/a> <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25565443\/\" data-mce-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25565443\/\">a expectativa de vida<\/a>.<\/p>\n<p>\u201cO impacto na vida dos pacientes \u00e9 expressivo, pois a doen\u00e7a reduz de forma significativa a qualidade de vida em compara\u00e7\u00e3o \u00e0 popula\u00e7\u00e3o geral, especialmente em pacientes com met\u00e1stases cerebrais. Este impacto torna ainda mais crucial a escolha de tratamentos eficazes que ofere\u00e7am uma resposta sustent\u00e1vel\u201d, afirma Vivian Lee, diretora m\u00e9dica da Takeda Brasil.<\/p>\n<p>Por isso, a Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (Conitec\/SUS) abriu as <strong>Consultas P\u00fablicas n\u00ba 78 e n\u00ba 84<\/strong>, que disp\u00f5em sobre inibidores da tirosina quinase para o tratamento de c\u00e2ncer de pulm\u00e3o n\u00e3o pequenas c\u00e9lulas com transloca\u00e7\u00e3o ALK (CPNPC ALK+) em est\u00e1gio avan\u00e7ado ou metast\u00e1tico, como primeira e segunda linhas de tratamento. As sociedades civil e m\u00e9dica podem exercer seu direito e manifestar opini\u00f5es sobre a proposta at\u00e9 o dia 11\/12, pelo site da <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/www.gov.br\/conitec\/pt-br\/assuntos\/participacao-social\/consultas-publicas\" data-mce-href=\"https:\/\/www.gov.br\/conitec\/pt-br\/assuntos\/participacao-social\/consultas-publicas\">Conitec<\/a>.<\/p>\n<p>A <a rel=\"follow noopener\" target=\"_blank\" href=\"https:\/\/www.gov.br\/saude\/pt-br\/acesso-a-informacao\/participacao-social\/consultas-publicas\" data-mce-href=\"https:\/\/www.gov.br\/saude\/pt-br\/acesso-a-informacao\/participacao-social\/consultas-publicas\">consulta p\u00fablica<\/a> \u00e9 um mecanismo de participa\u00e7\u00e3o social, de car\u00e1ter consultivo, realizado com prazo definido e aberto a qualquer interessado, que incentiva a participa\u00e7\u00e3o da sociedade na tomada de decis\u00f5es relativas \u00e0 formula\u00e7\u00e3o e defini\u00e7\u00e3o de pol\u00edticas p\u00fablicas.<\/p>\n<p>Essa, em especial, \u00e9 uma oportunidade para que todos possam compartilhar informa\u00e7\u00f5es e opini\u00f5es que contribuam para esse processo de avalia\u00e7\u00e3o de incorpora\u00e7\u00e3o de novas tecnologias pela Comiss\u00e3o. Por meio da an\u00e1lise multidrogas foram avaliadas, simultaneamente, a efic\u00e1cia das terapias dispon\u00edveis para o paciente, assim como o custo-benef\u00edcio para o sistema de sa\u00fade.&nbsp;<\/p>\n<p>\u201cA inova\u00e7\u00e3o em sa\u00fade s\u00f3 se concretiza quando est\u00e1 acess\u00edvel a todos no momento em que mais precisam e de maneira sustent\u00e1vel. Essas consultas p\u00fablicas representam uma oportunidade para avan\u00e7armos na equidade, possibilitando que tratamentos mais recentes para o CPNPC ALK+ melhorem a qualidade de vida desses pacientes\u201d, complementa a diretora m\u00e9dica da Takeda Brasil,&nbsp;Vivian&nbsp;Lee.<\/p>\n<p><img src='https:\/\/api.dino.com.br\/v2\/news\/tr\/310931?partnerId=3197' alt=\"\" style=\"border:0px;width:1px;height:1px;\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>O c\u00e2ncer de pulm\u00e3o \u00e9 o segundo tipo de c\u00e2ncer mais diagnosticado no mundo e foi a principal causa de mortes por c\u00e2ncer em 2020. No Brasil, \u00e9 o terceiro mais comum em homens e o quarto em mulheres, totalizando 32.560 novos casos em 2023, com uma taxa de sobrevida de 18% em cinco anos. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":24892,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-24891","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\" \/>\n<meta property=\"og:description\" content=\"O c\u00e2ncer de pulm\u00e3o \u00e9 o segundo tipo de c\u00e2ncer mais diagnosticado no mundo e foi a principal causa de mortes por c\u00e2ncer em 2020. No Brasil, \u00e9 o terceiro mais comum em homens e o quarto em mulheres, totalizando 32.560 novos casos em 2023, com uma taxa de sobrevida de 18% em cinco anos. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/\" \/>\n<meta property=\"og:site_name\" content=\"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-05T21:15:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/api.dino.com.br\/v2\/news\/tr\/310931?partnerId=3197\" \/>\n<meta name=\"author\" content=\"DINO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"DINO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/\"},\"author\":{\"name\":\"DINO\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\"},\"headline\":\"Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro\",\"datePublished\":\"2024-12-05T21:15:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/\"},\"wordCount\":503,\"image\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2f060d14-bb33-4eb9-bb21-bf84feef2760.jpg\",\"articleSection\":[\"Not\u00edcias Corporativas\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/\",\"name\":\"Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2f060d14-bb33-4eb9-bb21-bf84feef2760.jpg\",\"datePublished\":\"2024-12-05T21:15:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2f060d14-bb33-4eb9-bb21-bf84feef2760.jpg\",\"contentUrl\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2f060d14-bb33-4eb9-bb21-bf84feef2760.jpg\",\"width\":1134,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#website\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/\",\"name\":\"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\",\"description\":\"Tudo sobre o mercado empresarial, comunicados e neg\u00f3cios\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\",\"name\":\"DINO\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"caption\":\"DINO\"},\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/author\\\/dino\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/","og_locale":"pt_BR","og_type":"article","og_title":"Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","og_description":"O c\u00e2ncer de pulm\u00e3o \u00e9 o segundo tipo de c\u00e2ncer mais diagnosticado no mundo e foi a principal causa de mortes por c\u00e2ncer em 2020. No Brasil, \u00e9 o terceiro mais comum em homens e o quarto em mulheres, totalizando 32.560 novos casos em 2023, com uma taxa de sobrevida de 18% em cinco anos. [&hellip;]","og_url":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/","og_site_name":"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","article_published_time":"2024-12-05T21:15:58+00:00","og_image":[{"url":"https:\/\/api.dino.com.br\/v2\/news\/tr\/310931?partnerId=3197","type":"","width":"","height":""}],"author":"DINO","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"DINO","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/#article","isPartOf":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/"},"author":{"name":"DINO","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff"},"headline":"Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro","datePublished":"2024-12-05T21:15:58+00:00","mainEntityOfPage":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/"},"wordCount":503,"image":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/#primaryimage"},"thumbnailUrl":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-content\/uploads\/2024\/12\/2f060d14-bb33-4eb9-bb21-bf84feef2760.jpg","articleSection":["Not\u00edcias Corporativas"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/","url":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/","name":"Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","isPartOf":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/#primaryimage"},"image":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/#primaryimage"},"thumbnailUrl":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-content\/uploads\/2024\/12\/2f060d14-bb33-4eb9-bb21-bf84feef2760.jpg","datePublished":"2024-12-05T21:15:58+00:00","author":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff"},"breadcrumb":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/#primaryimage","url":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-content\/uploads\/2024\/12\/2f060d14-bb33-4eb9-bb21-bf84feef2760.jpg","contentUrl":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-content\/uploads\/2024\/12\/2f060d14-bb33-4eb9-bb21-bf84feef2760.jpg","width":1134,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/consultas-publicas-ampliam-cenarios-para-cancer-ultrarraro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ocanal.com\/noticias\/corporativas\/"},{"@type":"ListItem","position":2,"name":"Consultas p\u00fablicas ampliam cen\u00e1rios para c\u00e2ncer ultrarraro"}]},{"@type":"WebSite","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#website","url":"https:\/\/ocanal.com\/noticias\/corporativas\/","name":"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","description":"Tudo sobre o mercado empresarial, comunicados e neg\u00f3cios","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ocanal.com\/noticias\/corporativas\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff","name":"DINO","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","caption":"DINO"},"url":"https:\/\/ocanal.com\/noticias\/corporativas\/author\/dino\/"}]}},"_links":{"self":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts\/24891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/comments?post=24891"}],"version-history":[{"count":0,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts\/24891\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/media\/24892"}],"wp:attachment":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/media?parent=24891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/categories?post=24891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/tags?post=24891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}